Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement
Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line - Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s Disease and other indications.
In the venture studio model developed by Argobio, breakthrough technologies are embraced by a team of scientific experts with an entrepreneurial and industrial experience. Over the course of incubation, Argobio will fund the project development up to 3 ME and incorporate the start-up. After incubation, further venture funding will be provided by specialized VC investors.
“The launch of our first collaboration is a great achievement for Argobio. Argobio intends to incubate until series A at least five projects in the fields of rare diseases, neurosciences, and oncology over the next three years. With a committed capital of €50 million, and a team of pharma industry experts, Argobio expects to deliver strong projects, well-prepared for Series A funding,” Thierry Laugel Argobio Chairman said.
GeneCode, a discovery-stage biotech company developing small molecule GDNF mimetics, in collaboration with the laboratory of Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland, has identified and patented a series of small molecules activating the GDNF signalling receptor RET tyrosine kinase. Professor Saarma´s team has discovered GDNF receptors, clarified the GDNF-receptor structure and investigated the therapeutic potential of GDNF family members.
Professor Mart Saarma commented, “Argobio’s investment and participation in the development of effective GDNF mimetics is extremely encouraging news. GDNF mimetics can overcome the limitations of the GDNF protein and can open up a completely new page in the treatment of Parkinson’s disease.”
GeneCode CEO Paavo Pilv added, “ Our combined expertise will catapult this technology beyond what we would have been able to achieve alone. Considering the pivotal role of GDNF family ligands and RET signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited only to Parkinson’s Disease but can be applied to treat other medical conditions.”
“We have ambitious goals for the next two years,” Argobio Entrepreneur in Residence Yves Ribeill, PhD said. “The whole is greater than the sum of the parts with the combined, diverse expertise of GeneCode, Argobio and Professor Saarma. I am confident that we will be able to demonstrate that the unique business model of funded partnerships initiated by Argobio in Europe will give new therapeutics a boost to succeed.”
About Argobio: www.argobiostudio.com
Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop (or lead) them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.
Follow us on LinkedIn.
About GeneCode: www.GeneCode.com
GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Yves Ribeill – firstname.lastname@example.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westmount Realty Capital Recapitalizes 6.1 Million Square-Foot Industrial Portfolio in Chicago and Milwaukee26.1.2022 21:33:00 EET | Press release
Westmount Realty Capital, a privately held, Dallas-based commercial real estate company announced today that it is partnering with a fund managed by the Real Estate Group of Ares Management Corporation, a leading global alternative investment manager, to recapitalize a 51-asset industrial portfolio totaling 6.1 million square feet located in established industrial submarkets of Chicago and Milwaukee. Westmount and Ares acquired the institutional-quality portfolio of logistics, bulk distribution, and last-mile industrial properties from a Partners Group Westmount joint venture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005816/en/ Westmount Realty Capital and Ares Management Corporation recapitalized and acquired an institutional-quality portfolio of logistics, bulk distribution, and last-mile industrial properties totaling 6.1 million square feet located in established industrial submarkets of Chicago and Milwaukee
artnet AG: Artnet Joins New Deutsche Börse ESG Visibility Hub26.1.2022 20:25:00 EET | Press release
Artnet AG, the leading platform for art market data and media, and the global marketplace for fine art online-only sales, is pleased to announce that it has joined the new Deutsche Börse ESG Visibility Hub. Investors increasingly expect transparency from companies with regard to sustainability. A high level of disclosure and comprehensible reporting enables ESG-related data (ESG translates to Environment, Society, Governance) to be included in investment decisions - with the aim of lowering the risks and positive impact of an investment. Artnet AG has been a pioneer within the art market for over 30 years. By engaging with ESG reporting and initiatives, Artnet continues its ethos of spearheading positive change and sustainable business practices. Artnet strives to continuously offer an environment where its employees, customers, and stakeholders can do what they love in a sustainable way. Furthermore, Artnet values its role in assisting clients in engaging with fine art and collectible
VitreaLab, Quantopticon, Luminess Win Big at SPIE Startup Challenge26.1.2022 19:35:00 EET | Press release
Yesterday, at a ceremony during SPIE Photonics West, VitreaLab, with its laser-lit chip focused on the 2D and 3D display market – a technology which enables more power-efficient displays – was announced the winner of the $10,000 top prize at the 12th annual SPIE Startup Challenge. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005652/en/ Jonas Zeuner of VitreaLab, center, is joined onstage by Jenoptik's Song Yop Chung, left, and Ralf Kuschnereit, right. (Photo: Business Wire) With cash prizes all provided by Jenoptik, Quantopticon, a designer of simulation software for quantum photonic hardware manufacturers, received $5,000 for second place. Luminess came in third, winning $2,500, with their versatile platform for safer, more sensitive, and more reliable X-ray medical imaging. The SPIE Startup Challenge, which showcases new businesses, products, and technologies that address critical needs with photonics, is supported
ABO - Óskare Capital: Partnership Announcement26.1.2022 17:30:00 EET | Press release
Alpha Blue Ocean (ABO) and Óskare Capital are announcing today the formation of a strategic partnership to collaborate on investment opportunities associated with cannabis plant-based medicines as well as synthetic molecules that target the mammalian Endocannabinoid system (ECS). Both companies recognize that there are also investment opportunities related to products, infrastructure technologies and services which will be part of the associated ecosystem for this sector. With a strong focus in Europe, the teams will work together to identify those companies with the greatest potential to enter global markets. This sector is nascent in Europe and is still in early stages of development on the pharmaceutical side; both companies see this as a “blue ocean” opportunity as the market emerges in the years to come. The partnership is based on biotech, agtech, and life science expertise; track records in the European VC; and strong access to deal flow, all of which will enable the partnership
Staffmark Group Leverages Rimini Street Support for Oracle PeopleSoft Powering Payroll for 35,000 Employees a Week26.1.2022 17:00:00 EET | Press release
Rimini Street, Inc. (NASDAQ: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Staffmark Group, an award-winning staffing and recruitment firm, continues to leverage Rimini Street to support the company’s PeopleSoft system environment support and maintenance. Since making the switch to Rimini Street, Staffmark has significantly improved the quality, responsiveness and depth of PeopleSoft support available to its internal IT team, enabled faster tax, legal and regulatory updates, and plans to reinvest support cost savings in service offering innovation and enhancements such as AI analysis capabilities and automated job posting functionality for employers and jobseekers – a vital part of its competitive market strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005280/en/
Covetrus Taps César França as President, Global Proprietary Brands26.1.2022 17:00:00 EET | Press release
Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of César França as President, Global Proprietary Brands. França will lead the companywide development and management of Covetrus’ global proprietary brand portfolio, including the current Covetrus, Kruuse, Vi, Roadrunner Pharmacy, and Calibra brands. The company will rely on his vision and expertise to develop categories, build strategic partnerships, and identify external growth opportunities. França brings more than 25 years of leadership and experience in brand development and management, marketing, sales, business development, and general management to Covetrus. “We’re delighted to welcome César to this new and dynamic role,” said Matt Malenfant, Chief Commercial Officer at Covetrus. “César is a positive, trusted leader with a foundational belief in the power of people and brands. He will work closely with our commercial and operations teams to ensure effectiveness an
o9 Solutions Raises $295 Million From Strategic Investors to Continue its Growth Across Industry Verticals & Markets26.1.2022 16:00:00 EET | Press release
o9 Solutions, a leading enterprise AI software platform provider for transforming planning and decision-making speed and quality in companies across industry verticals, today announced that it has received equity investments totaling $295 million from General Atlantic, including BeyondNetZero, its climate investing venture, Generation Investment Management, a pure-play sustainability investment manager, and existing investor KKR. This significant investment will help o9 build on its momentum and accelerate growth for its AI-powered Integrated Business Planning platform it calls the “Digital Brain” across industry verticals and markets. It will also help o9 drive continued innovation in R&D, industry knowledge models and partner ecosystem development that will help companies implement o9’s game-changing platform faster and realize greater value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005218/en/ Chakri Gottemukka
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom